🏛️ Verified NIH Record • Updated 2026-08-10

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (NCT02436707)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Canadian Cancer Trials Group

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to find out what effects new combinations of treatment will have this disease. New promising treatment strategies will be added to this study as they are available to be compared against the standard treatment.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (20 items) and avoid the listed exclusions (13 items).

Location: Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer and superficial bladder cancer, curatively treated in-situ cancer of the cervix or breast, or localized excised prostate cancer, other solid tumours curatively treated with no evidence of disease for ≥ 3 years.
  • Active and uncontrolled central nervous system involvement, meningeal or parenchymal. Patients with CNS disease at initial presentation and who are in a CNS CR at the time of relapse are eligible. MRI scanning and / or lumbar puncture should be performed if there is clinical suspicion of active CNS disease.
  • Major surgery performed within 10 days of randomization.
  • Known history of human immunodeficiency virus (HIV), active Hepatitis C Virus infection, active Hepatitis B Virus infection or any uncontrolled active systemic infection requiring intravenous (IV) antibiotics. Patients with Hepatitis B serology suggestive of infection are eligible if they are HBV DNA negative and concurrently treated with anti-viral therapy. Patients with a past history of hepatitis C who have eradicated the virus are eligible.
  • Patients who have been vaccinated with live, attenuated vaccines within 4 weeks of randomization.
  • Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification.
  • Any serious active disease or co-morbid medical condition, including psychiatric illness, judged by the local investigator to preclude safe administration of the planned protocol treatment or required follow-up.
  • Any other serious intercurrent illness, life threatening condition, organ system dysfunction, or medical condition judged by the local investigator to compromise the subject's safety, interfere with the absorption or metabolism of selinexor tablets, or preclude safe administration of the planned protocol treatment or required follow-up, including (for example):
  • active, uncontrolled bacterial, fungal, or viral infection;
  • clinically significant cardiac dysfunction or cardiovascular disease.
  • Pregnant or lactating females, or women of childbearing potential not willing to use an adequate method of birth control for the duration of the study.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (11 Sites)

  • Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
  • Cross Cancer Institute — Edmonton, Alberta
  • BCCA - Vancouver — Vancouver, British Columbia
  • CancerCare Manitoba — Winnipeg, Manitoba
  • QEII Health Sciences Centre — Halifax, Nova Scotia
  • Kingston Health Sciences Centre — Kingston, Ontario
  • Ottawa Hospital Research Institute — Ottawa, Ontario
  • University Health Network — Toronto, Ontario
  • CHUM-Centre Hospitalier de l'Universite de Montreal — Montreal, Quebec
  • CHU de Quebec-Hopital l'Enfant-Jesus (HEJ) — Québec, Quebec
  • Allan Blair Cancer Centre — Regina, Saskatchewan

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗